Prihlásiť sa Zaregistrujte sa zadarmo

1 ročný cieľ spoločnosti Adaptimmune Therapeutics Plc

Aká je hodnota metriky 1 ročný cieľ spoločnosti Adaptimmune Therapeutics Plc?

Hodnota metriky 1 ročný cieľ spoločnosti Adaptimmune Therapeutics Plc je $11 +949.07%

Aká je definícia metriky 1 ročný cieľ?

1-ročný cieľ (1-year target) je analytikmi predpokladaná cena akcie za rok od dnešného dňa.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1 ročný cieľ spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Adaptimmune Therapeutics Plc

Čomu sa venuje spoločnosť Adaptimmune Therapeutics Plc?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Firmy s metrikou 1 ročný cieľ podobnou spoločnosti Adaptimmune Therapeutics Plc